The Longevity Podcast: Optimizing HealthSpan & MindSpan

Inside The Alzheimer’s Maze

• Dung Trinh

Share episode

Send us a text

We map how Alzheimer’s disrupts the brain’s wiring, how symptoms progress from memory slips to loss of judgment and orientation, and why ruling out treatable look-alikes can change the story. We also weigh proven medications, cautious new therapies, and the daily practices that protect function and dignity.

• biology of plaques, tangles, and acetylcholine loss
• early, middle, and late symptom patterns
• risks that rise with age, family history, and genes
• diagnosis built on history, cognitive tests, and imaging
• reversible mimics including B12 deficiency and hypothyroidism
• cholinesterase inhibitors and memantine for symptom management
• monoclonal antibodies, potential benefits, and MRI-monitored risks
• lifestyle strategies: exercise, cognitive activity, Mediterranean-style diet
• caregiver playbook: familiar routines, safe home, music and art engagement


This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.

Never miss an episode—subscribe on your favorite podcast app!

SPEAKER_01:

Welcome to the deep dive. Today we're tackling a subject that is often incredibly complex and for many deeply personal, Alzheimer's disease.

SPEAKER_00:

Aaron Ross Powell It really is.

SPEAKER_01:

We've pulled our information from some crucial, very detailed source material from experts at Harvard Health because we know you want to approach this with real knowledge, but without getting lost in all of the medical jargon.

SPEAKER_00:

Aaron Powell That's right. And our goal for this deep dive is well, it's pretty clear. We want to move beyond just the basic definition. We're going to try and unpack the biological progression of Alzheimer's or AD and uh clarify the diagnostic methods, which can be tricky.

SPEAKER_01:

Aaron Powell And then get into the really current stuff, the treatment and prevention strategies that are evolving so quickly.

SPEAKER_00:

Exactly.

SPEAKER_01:

So AD is the most common form of dementia. Our sources define it as an irreversible loss of brain functions that just gets progressively worse over time. It typically starts after age 60, but what is actually happening inside the brain to trigger this collapse?

SPEAKER_00:

Aaron Powell At its core, it's a tragedy of communication failure within the brain. The very first function that's almost always affected is short-term memory.

SPEAKER_01:

Aaron Powell That mental filing system you use every minute.

SPEAKER_00:

Aaron Ross Powell Exactly that. The one that lets you recall what you just heard or where you put your keys a second ago. As that starts to erode, it um it gradually impairs other intellectual abilities.

SPEAKER_01:

Aaron Powell So things like language, problem solving.

SPEAKER_00:

Trevor Burrus Yes. And eventually it leads to severely impaired judgment.

SPEAKER_01:

Aaron Powell So we know the result is this intellectual failure, but let's dig into the biology. What's the cause of this system-wide failure? The sources seem to point to both a physical and a chemical breakdown.

SPEAKER_00:

Aaron Powell Absolutely.

SPEAKER_01:

Yeah.

SPEAKER_00:

And what makes AD such a well such a challenging puzzle is that we don't have one single undisputed trigger. What researchers have identified, though, are two primary culprits. Two proteins? Two proteins that start accumulating in, frankly, toxic amounts. They essentially begin to suffocate the brain's communication network.

SPEAKER_01:

Aaron Powell Okay, and this is where we need to give you the specific vocabulary. It's not just two proteins, is it?

SPEAKER_00:

Correct. So the first protein is called amyloid beta. When it builds up too much, it forms these dense, sticky clusters outside the brain cells.

SPEAKER_01:

And these are the famous plaques?

SPEAKER_00:

These are the plaques. You can think of them like, I don't know, massive road construction that just completely jams up all the neural traffic.

SPEAKER_01:

Okay, that's a clear image. And the second protein.

SPEAKER_00:

The second is tau. And this one is different. It starts twisting into these abnormal fibers inside the brain cells, and that forms what we call neurofibrillary tangles.

SPEAKER_01:

So if the plaques are traffic jam outside the cell.

SPEAKER_00:

Then the tangles are internal structural damage. It's like the support beams of the cell twisting and buckling until the whole structure just collapses from within.

SPEAKER_01:

Wow. So it's a physical traffic jam outside and a structural failure inside. That's devastating.

SPEAKER_00:

That's the physical component, yes. But we also see a chemical problem. Our sources r really emphasize the role of acetylcholine.

SPEAKER_01:

Which is a neurotransmitter.

SPEAKER_00:

A critical one. It's basically the chemical messaging service between brain cells. In patients with AD, acetylcholine levels just plummet, which makes the communication failure from the plaques entangles even worse.

SPEAKER_01:

Aaron Powell So you have a physical block and a chemical shortage.

SPEAKER_00:

Exactly. And the um the end result of that double whammy is that the brain cells themselves start to shrivel and eventually they die.

SPEAKER_01:

Aaron Powell Before we track how this looks from the outside, the symptoms, let's just quickly touch on who is most susceptible. What does the research say about risk factors?

SPEAKER_00:

Aaron Ross Powell The risk factors are uh pretty crucial for understanding the whole landscape. The biggest one, not surprisingly, is simply increasing age. The risk just climbs dramatically after 65.

SPEAKER_01:

And there's a family connection?

SPEAKER_00:

Strong one. Having a parent or a sibling with AD significantly raises your personal risk. And then finally, there are certain specific genetic factors you can inherit that just make you more vulnerable.

SPEAKER_01:

Okay, so let's connect that internal biology to the outward experience. AD is progressive. The symptoms follow this, well, this distinct and often heartbreaking timeline. How do the sources break down the stages?

SPEAKER_00:

We can draw a pretty clear line between the early stages, where a person can still be surprisingly independent, and the later, more debilitating stages.

SPEAKER_01:

So what does that early phase look like?

SPEAKER_00:

In the earliest phase, the challenges are almost all focused on acquiring new memories and trying to retain new information.

SPEAKER_01:

So they might repeat stories or forget a conversation they just had?

SPEAKER_00:

Precisely. Or struggle to learn a new recipe, something like that.

SPEAKER_01:

So if they're forgetting what they had for breakfast, that's early stage. But they can still, say, button their own shirt.

SPEAKER_00:

That is the crucial nuance right there. A person in early AD usually retains their ability to manage their daily physical needs. They can feed themselves, bathe, dress, groom, all without assistance.

SPEAKER_01:

The operating system is failing, but the hardware, the motor functions, they're still working.

SPEAKER_00:

A great way to put it. The basic self-care is still intact.

SPEAKER_01:

So when does that change? When does the deterioration move into those middle and later stages?

SPEAKER_00:

Aaron Powell That's when the brain's executive functions really begin to collapse. The loss shifts from just new memories to the gradual erasure of older, more distant memories.

SPEAKER_01:

And this is where complex tasks become impossible.

SPEAKER_00:

Exactly. Things that require planning in sequence: managing a budget, preparing a meal with multiple steps, or just remembering the sequence of taking daily medication.

SPEAKER_01:

And I know a big one for caregivers is the loss of spatial awareness.

SPEAKER_00:

It is a huge source of anxiety. The sources highlight the danger of losing your sense of direction, even in a place that's completely familiar, like your own neighborhood.

SPEAKER_01:

Or even your own house.

SPEAKER_00:

Yes, it's a profound loss of that internal map we all have.

SPEAKER_01:

And beyond memory and function, the psychological and behavioral changes seem, I mean, they seem just as devastating.

SPEAKER_00:

They often are for everyone involved. We frequently see personality changes, um, things like irritability, escalating anxiety, or really profound depression in the earlier phases.

SPEAKER_01:

But it gets more severe.

SPEAKER_00:

It does. As the disease moves into the middle and late stages, these symptoms can escalate pretty severely.

SPEAKER_01:

We're talking about delusions and hallucinations here. That must be incredibly difficult to manage.

SPEAKER_00:

Incredibly. Delusions are these irrational beliefs. A patient might sincerely believe someone is stealing from them or that they're being persecuted. Hallucinations are sensory experiences that just aren't real seeing or hearing things.

SPEAKER_01:

And this can lead to things like aggression.

SPEAKER_00:

It can, and it's often combined with a very dangerous tendency to wander away from home. It just requires immense, constant protective care.

SPEAKER_01:

Aaron Ross Powell That thought, that level of cognitive distress really brings home how difficult this diagnosis must be, which is where we should go now. Let's unpack this. The affected person often doesn't recognize there's a problem, right? They might even deny it.

SPEAKER_00:

It's very common, yes.

SPEAKER_01:

So how is a diagnosis of AD actually reached? It must rely so heavily on family and friends.

SPEAKER_00:

It absolutely does. The diagnosis really relies on the history gathered from the people who see the person every day, the ones who can report on memory lapses, poor judgment, or personality changes. The family is the cornerstone.

SPEAKER_01:

And the big challenge, which are sources stress, is that there is no single definitive test for Alzheimer's. You can't just get a blood test that gives you a yes or no.

SPEAKER_00:

That is correct. The diagnosis is clinical. It's built on, well, on exclusion and compiled evidence. A doctor will start with a medical history, a physical and neurological exam, and what's called a mental status exam.

SPEAKER_01:

Simple cognitive tests.

SPEAKER_00:

Right. Simple tests involving visual tasks, writing, and memory checks.

SPEAKER_01:

Aaron Powell But, and this feels like the most critical part of this section for anyone listening. Before a doctor even considers an irreversible diagnosis of AD, they have to rule out other conditions that can look just like it.

SPEAKER_00:

This step is profoundly important. It is, frankly, the only chance for a truly treatable, reversible diagnosis.

SPEAKER_01:

Aaron Powell And what's fascinating is that the sources pinpoint two specific conditions that can perfectly mimic AD symptoms.

SPEAKER_00:

They can. And if they're caught, the outcome is completely different. We're talking about very low levels of vitamin B12 or a very underactive thyroid, also known as hypothyroidism.

SPEAKER_01:

Wait, so a vitamin deficiency or a thyroid issue can cause cognitive decline severe enough that it looks like Alzheimer's?

SPEAKER_00:

That is precisely the danger and also the hope. The incredibly important takeaway for you is that the memory and thinking problems from these issues can improve and even go away entirely with treatment.

SPEAKER_01:

Wow. So if a doctor skips that step, those simple blood tests.

SPEAKER_00:

They might unnecessarily doom a patient to an irreversible diagnosis when the real problem is entirely fixable.

SPEAKER_01:

That makes the blood work just about the most important tool in the whole process. It's like checking the oil before you declare the engine is broken for good.

SPEAKER_00:

A perfect analogy. So if those simple tests come back clean, but cognitive problems are still there, what's next?

SPEAKER_01:

Right. What's the next step?

SPEAKER_00:

They might move on to more detailed neuropsychological testing, which is a much deeper dive into cognition, and they'll almost certainly order brain imaging studies, a CT scan or an MRI.

SPEAKER_01:

But it's vital to understand what these scans can and maybe more importantly, cannot do.

SPEAKER_00:

Yes. They cannot diagnose AD with certainty.

SPEAKER_01:

But they rule other things out.

SPEAKER_00:

Exactly. They are critical for ruling out other structural causes, things like a brain tumor or evidence of a stroke. The scans can show brain shrinkage or atrophy, which supports a clinical diagnosis of AD, but it's still not definitive proof.

SPEAKER_01:

And the diagnosis is usually confirmed by a specialist.

SPEAKER_00:

Yes, after referral to a neurologist, a geriatrician, or maybe a geriatric psychiatrist.

SPEAKER_01:

Aaron Powell So the picture is clear. AD is irreversible. Function declines until death. The goal has to shift entirely to management. What do the sources say about providing some hope, both in delaying the onset and slowing it down once it starts?

SPEAKER_00:

Let's start with prevention, or maybe more accurately, delaying the onset of symptoms. The evidence we have strongly supports simple lifestyle factors that you can control right now.

SPEAKER_01:

Like staying active.

SPEAKER_00:

Staying physically and mentally active is key. Regular physical exercise, particularly aerobic exercise, seems to be very protective.

SPEAKER_01:

And diet always comes up in these conversations.

SPEAKER_00:

He does. The sources specifically highlight a dietary pattern, kind of like a Mediterranean style. They emphasize a diet with plenty of fish, olive oil, and lots of vegetables.

SPEAKER_01:

So this is about delaying onset and maybe slowing progression.

SPEAKER_00:

It seems to be, yes. It just underscores that what's good for your heart and your vascular health is also really good for your brain.

SPEAKER_01:

Okay, let's shift to treatment for those already diagnosed. What are the workhorse drugs that aim to slow the decline?

SPEAKER_00:

For mild to moderate AD, we rely on a class of drugs called cholinesterase inhibitors. Now, since we said acetylcholine, the brain's messenger, is in short supply.

SPEAKER_01:

Right.

SPEAKER_00:

These drugs work by inhibiting the enzyme that breaks it down.

SPEAKER_01:

So you're basically preserving what little of the messenger chemical is left.

SPEAKER_00:

That's a great way to think about it. You're helping the brain make the most of its existing supply. For moderate to severe AD, there's also a drug called mementine, which works a bit differently to help stabilize memory.

SPEAKER_01:

And now we have to talk about the newer, more complex therapies, the ones that have been all over the news. This is where we need to be cautiously optimistic. The monoclonal antibodies.

SPEAKER_00:

We are. We're talking specifically about aducanimab, aduhelm, and the newer one, Lacanimab, um, Gipsula. Both got accelerated FDA approval.

SPEAKER_01:

And unlike the other drugs that just manage symptoms, these are designed to attack the underlying problem.

SPEAKER_00:

Exactly. They target and try to clear out those amyloid beta protein deposits we talked about earlier, the plaques.

SPEAKER_01:

The hope being if you clear the plaques, you might slow or even halt the disease's progression. But the sources are very clear that we have to stress the caution around these drugs.

SPEAKER_00:

We absolutely must. While they represent a huge leap forward in targeting the disease mechanism itself, they come with significant risks. The main concern is something called amylaid-related imaging abnormalities or ARAA.

SPEAKER_01:

ARAA, and what is that?

SPEAKER_00:

It refers to side effects you can see on brain scans, specifically brain swelling or microhemorrhages, tiny little bleeds in the brain.

SPEAKER_01:

That sounds extremely serious.

SPEAKER_00:

It is. Patients on these drugs have to be monitored with regular MRI scans to catch these things early. It really turns the treatment decision into a very careful risk versus reward calculation.

SPEAKER_01:

So beyond the pharmaceuticals, supportive non-drug care is still absolutely essential.

SPEAKER_00:

It's paramount. The supportive environment is everything. Caregivers need to maintain familiar surroundings, people, and routines. Too much change can trigger confusion and agitation.

SPEAKER_01:

And creating safe environments to manage things like laundering.

SPEAKER_00:

Critical. And also making sure the patient stays engaged, even as their abilities fade.

SPEAKER_01:

Through things like music or art therapy.

SPEAKER_00:

Precisely. Music, art, occupational therapy. They all provide essential stimulation and can offer real emotional outlets. It really takes a whole team.

SPEAKER_01:

This deep dive has really given us a much clearer picture of AD from the biology of plaques and tangles all the way to the cutting edge of these new, if controversial, therapies.

SPEAKER_00:

I hope so.

SPEAKER_01:

And I think most importantly, we've highlighted that critical need for a proper diagnosis, making sure to rule out treatable conditions like a B12 deficiency or thyroid issues before accepting that irreversible diagnosis.

SPEAKER_00:

Alzheimer's remains a severe challenge, there's no doubt. But this kind of informed approach, combining lifestyle efforts, early and comprehensive diagnosis, and the uh the careful use of modern treatments, that offers the most critical path forward.

SPEAKER_01:

And that leaves us with a final provocative thought for you to consider as you reflect on all this. If optimized lifestyle choices, physical and mental activity, diet, and exercise, are scientifically shown to delay the onset of symptoms and slow disease progression later in life, how much earlier in life does the compounding biological benefit of an optimized lifestyle truly begin? Something for you to mull over until our next deep dive.